Olmesartán/Hidroclorotiazida Normon (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartán/Hidroclorotiazida Normon, is an angiotensin II receptor blocker presented as a oral tablet for hypertension management in adults. It combines olmesartan with a thiazide diuretic to improve blood pressure control.

GNH USA supplies Olmesartán/Hidroclorotiazida Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/hydrochlorothiazide is used in cardiovascular therapy to lower blood pressure through combined angiotensin II blockade and diuresis. - Hypertension: helps achieve target blood pressure when monotherapy is insufficient. - Heart failure with reduced ejection fraction: used as part of a regimen to reduce fluid overload and improve outcomes. - Diabetic nephropathy: assists in slowing progression by controlling hypertension and reducing intraglomerular pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild renal function changes

Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Acute kidney injury - Hyperkalemia - Severe electrolyte imbalance - Hepatic dysfunction

When prescribing olmesartan/hydrochlorothiazide, clinicians should consider several safety aspects. - Renal impairment: adjust dose or monitor function regularly. - Electrolyte balance: check serum potassium and sodium periodically. - Hepatic disease: use with caution in patients with liver dysfunction. - Pregnancy: contraindicated in the second and third trimesters. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartan/hydrochlorothiazide may interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Potassium‑rich supplements or salts: risk of hyper‑kalaemia. - Aliskiren combined with ACE inhibitors or ARBs in diabetic patients: increased renal risk. - NSAIDs (high‑dose): may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Lithium: may increase serum lithium levels. - Other antihypertensives: additive blood‑pressure lowering effect. - Antidiabetic drugs: may enhance hypoglycaemic effect. - Loop diuretics: combined diuretic effect may cause electrolyte loss. - CYP3A4 inhibitors: may modestly increase olmesartan exposure.